Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high-risk chronic hepatitis B patients for HCC surveillance in Thailand

泰国肝细胞癌(HCC)风险评分与HCC国家指南在识别高危慢性乙型肝炎患者进行HCC监测方面的比较

阅读:1

Abstract

BACKGROUND AND AIM: Hepatocellular carcinoma (HCC) surveillance in hepatitis B virus (HBV) patients is currently based on age/sex/cirrhosis, uses ultrasound abdomen every 6-12 months, and is a resource burden. HCC risk scores have been developed to classify HCC risk for surveillance. The number of HBV patients needing surveillance when HCC risk scores are used may be different from the current recommendation with implications on the resources needed for HCC surveillance. METHODS: HBV patients from the liver clinic were included and classified as non-cirrhotic/cirrhotic and untreated/treated for analysis. Each subgroup was analyzed using REACH-B, CU-HCC, LSM-HCC, GAG-HCC, and mPAGE-B risk scores as appropriate. The change in the number of patients needing HCC surveillance using the above risk scores was calculated. RESULTS: Seven-hundred and thirteen HBV patients were included, of whom 361 (50.6%) were male with mean age 55.43 years, and 76 (10.7%) had cirrhosis. In the untreated, non-cirrhotic subgroup, the percentage change of patients needing HCC surveillance was -69.5, -58.9, -58.8, and -54.1% when GAG-HCC, LSM-HCC, CU-HCC, and REACH-B were used compared to traditional criteria, respectively. In the treated, non-cirrhotic subgroup, the percentage change of patients needing HCC surveillance decreased by -80, -75.2, -75.2, and -2.8% when GAG-HCC, CU-HCC, REACH-B, and mPAGE-B were used, respectively. For the cirrhotic group, HCC risk scores did not make much difference. CONCLUSION: The use of HCC risk scores in non-cirrhotic HBV patients reduced the number of patients needing surveillance greatly. HBV cirrhotic patients should have HCC surveillance without the need for risk score calculation. Patients with a family history of HCC should undergo surveillance until proven unnecessary in prospective trials.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。